

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

Voluntary Announcement

Received milestone payment for the partnership with UNITY Biotechnology

Ascentage Pharma Group International (the “**Company**” or “**Ascentage Pharma**”) is pleased to announce its global strategic cooperation partner, UNITY Biotechnology (“**UNITY**”, NASDAQ: UBX), has dosed the first patient in the United States in a Phase I clinical study of drug candidate UBX1325 in patients with diabetic macular edema (DME). UBX1325 is developed from BM-962, a Bcl-xL inhibiting compound licensed to UNITY by Ascentage Pharma for the treatment of age-related diseases.

This progress in clinical development qualified Ascentage Pharma for a milestone payment according to the licensing agreement entered into between Ascentage Pharma and UNITY. Pursuant to the terms of the licensing agreement, Ascentage Pharma is entitled to receive the milestone payment in common stocks from UNITY, totaling 228,310 shares.

This clinical trial conducted by UNITY is a Phase I, open-label, clinical study which is designed to evaluate the safety, tolerability, and pharmacokinetics of UBX1325 in patients with advanced DME. The trial plans to enroll approximately 15 patients, with safety and tolerability data expected in the first half of 2021. According to public information released by UNITY, preclinical tests have shown UBX1325 leads to a significant impact on senescent cells, reduction in vascular leakage, and improvement in retinal function.

In 2016, Ascentage Pharma and UNITY entered into strategic cooperation, among which, pursuant to a cooperation agreement in connection with compound library, UNITY has been authorized to screen Ascentage Pharma’s Bcl-2 series compounds for developing treatments for age-related diseases. The compound BM-962 was selected by UNITY as the compound to be used in the development of UBX1325. Pursuant to the applicable agreements, Ascentage Pharma retains the rights to such compound in the Greater China region and plans to establish a joint venture with UNITY in the future for the development of the Chinese market.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain further approval for, or ultimately market UBX1325 successfully.

By order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People's Republic of China, December 22, 2020

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng, Dr. Tian Yuan, Mr. Zhao Qun, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng and Mr. Ren Wei as independent non-executive Directors.